These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 8110626)

  • 1. Influences of lipid-modifying agents on hemostasis.
    Sirtori CR; Colli S
    Cardiovasc Drugs Ther; 1993 Nov; 7(5):817-23. PubMed ID: 8110626
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Randomized placebo-controlled study of the effects of simvastatin on haemostatic variables, lipoproteins and free fatty acids. The Oxford Cholesterol Study Group.
    Mitropoulos KA; Armitage JM; Collins R; Meade TW; Reeves BE; Wallendszus KR; Wilson SS; Lawson A; Peto R
    Eur Heart J; 1997 Feb; 18(2):235-41. PubMed ID: 9043839
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combination therapy with an HMG-CoA reductase inhibitor and a fibric acid derivative: a critical review of potential benefits and drawbacks.
    Farnier M
    Am J Cardiovasc Drugs; 2003; 3(3):169-78. PubMed ID: 14727929
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mechanisms of lipid-lowering agents.
    Sirtori CR; Manzoni C; Lovati MR
    Cardiology; 1991; 78(3):226-35. PubMed ID: 1868500
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacodynamics and pharmacokinetics of the HMG-CoA reductase inhibitors. Similarities and differences.
    Lennernäs H; Fager G
    Clin Pharmacokinet; 1997 May; 32(5):403-25. PubMed ID: 9160173
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Beyond low-density lipoprotein: addressing the atherogenic lipid triad in type 2 diabetes mellitus and the metabolic syndrome.
    Nesto RW
    Am J Cardiovasc Drugs; 2005; 5(6):379-87. PubMed ID: 16259526
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Management of protease inhibitor-associated hyperlipidemia.
    Penzak SR; Chuck SK
    Am J Cardiovasc Drugs; 2002; 2(2):91-106. PubMed ID: 14727985
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Choosing the right lipid-regulating agent. A guide to selection.
    Farmer JA; Gotto AM
    Drugs; 1996 Nov; 52(5):649-61. PubMed ID: 9118815
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Interactions between cyclosporin and lipid-lowering drugs: implications for organ transplant recipients.
    Asberg A
    Drugs; 2003; 63(4):367-78. PubMed ID: 12558459
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Atorvastatin in the treatment of primary hypercholesterolemia and mixed dyslipidemias.
    Yee HS; Fong NT
    Ann Pharmacother; 1998 Oct; 32(10):1030-43. PubMed ID: 9793596
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Optimal therapy of low levels of high density lipoprotein-cholesterol.
    Kashyap ML; Tavintharan S; Kamanna VS
    Am J Cardiovasc Drugs; 2003; 3(1):53-65. PubMed ID: 14727946
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Gemfibrozil. A reappraisal of its pharmacological properties and place in the management of dyslipidaemia.
    Spencer CM; Barradell LB
    Drugs; 1996 Jun; 51(6):982-1018. PubMed ID: 8736620
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lipid-lowering agents in proteinuric diseases.
    Appel GB; Appel AS
    Am J Nephrol; 1990; 10 Suppl 1():110-5. PubMed ID: 2256470
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The effects of lipid-lowering agents on acute renal allograft rejection.
    Kasiske BL; Heim-Duthoy KL; Singer GG; Watschinger B; Germain MJ; Bastani B
    Transplantation; 2001 Jul; 72(2):223-7. PubMed ID: 11477342
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Assessment of effects of lipid-lowering drugs on hemostasis.
    Altman R
    Am J Cardiol; 1998 Apr; 81(8A):73F-74F. PubMed ID: 9604916
    [No Abstract]   [Full Text] [Related]  

  • 16. New lipid-lowering agents acting on LDL receptors.
    Scharnagl H; März W
    Curr Top Med Chem; 2005; 5(3):233-42. PubMed ID: 15857307
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Drug interactions of lipid-altering drugs.
    Bays HE; Dujovne CA
    Drug Saf; 1998 Nov; 19(5):355-71. PubMed ID: 9825949
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of gemfibrozil and other fibric acid derivatives on blood lipids and lipoproteins.
    Zimetbaum P; Frishman WH; Kahn S
    J Clin Pharmacol; 1991 Jan; 31(1):25-37. PubMed ID: 2045526
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment of heterozygous familial hypercholesterolemia with lipid-lowering drugs.
    Illingworth DR; Bacon S
    Arteriosclerosis; 1989; 9(1 Suppl):I121-34. PubMed ID: 2492189
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Micronised fenofibrate: a review of its pharmacodynamic properties and clinical efficacy in the management of dyslipidaemia.
    Adkins JC; Faulds D
    Drugs; 1997 Oct; 54(4):615-33. PubMed ID: 9339964
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.